In particular, it has been shown that obese patients fail to achieve a low disease activity upon 6‐month treatment with TNF‐inhibitors (35.6% obese patients in the low disease activity group and 72% in the non‐low disease activity group, p = 0.004), although no correlation was observed in patients treated with an anti‐IL‐6, hinting that the response to the latter therapy may be independent of obesity [51]. Here, IL6 is linked to obesity due to melanocortin 4 receptor deficiency.